Mod­er­na touts 'su­pe­ri­or' an­ti­body lev­els against Omi­cron for au­tho­rized Covid-19 bi­va­lent boost­er

In Sep­tem­ber, Mod­er­na re­ceived FDA emer­gency use au­tho­riza­tion for its BA.4/BA.5-tar­get­ing bi­va­lent boost­er vac­cine, mR­NA-1273.222, based on pre­clin­i­cal da­ta for the shot as well as Phase II/III clin­i­cal tri­al da­ta study­ing a sim­i­lar bi­va­lent boost­er tar­get­ing the Omi­cron BA.1 sub­vari­ant.

Now, the mR­NA biotech says it has pos­i­tive clin­i­cal da­ta on mR­NA-1273.222 it­self to bur­nish the pro­file of the Covid-19 vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER